Aspire365

Aspire365 is a SAMHSA-registered addiction-treatment facility in New Haven, CT. The facility offers a continuum of care across multiple levels — Outpatient, MAT, Dual Dx — which means it can, in principle, hold a patient across the arc of a typical treatment episode. This page frames the questions that matter most when evaluating a specific program — the ones that separate useful candidates from marginal ones.

Care levels at Aspire365

The facility offers a continuum of care across multiple levels — Outpatient, MAT, Dual Dx — which means it can, in principle, hold a patient across the arc of a typical treatment episode. The practical question is whether it is genuinely strong at each level, or whether one level is the core business and the others are secondary. ASAM Criteria 4e is the benchmark framework for matching patients to appropriate intensity. Most major payer medical-necessity documents reference it. An outside ASAM-aligned assessment, prior to admission, is the protection against misplacement.

Insurance and payment

Aspire365 operates primarily on commercial insurance. The implication for patients: higher typical cost-share, potentially more intensive programming, and the full burden of MHPAEA parity-rule dynamics — including appeal rights when the plan denies. The operational prerequisite is written documentation: in-network status for your specific plan product, deductible accumulation, coinsurance rate, prior-authorization status. Admissions without these four documented carry material risk of post-admission financial disagreement.

Before you call

Three pre-admission questions for Aspire365: (1) at what ASAM 4e level are you admitting me, and what is the clinical rationale; (2) can you provide written Verification of Benefits for my specific plan; (3) what is your MAT policy for opioid use disorder — specifically, do you continue buprenorphine or methadone during residential programming. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.